Core Viewpoint - The recent stock transfer of Mace Health (02415) indicates a significant shift in shareholder structure, with a market value of HKD 88.21 million, representing 10.53% of the company [1] Financial Performance - Mace Health reported a revenue of RMB 125 million for the mid-term of 2025, reflecting a year-on-year growth of 13.2% [1] - The net profit reached RMB 13.239 million, showing a substantial increase of 5238.3% compared to the previous year [1] - The basic earnings per share were recorded at 2.45 cents, with a proposed interim dividend of 1.1 Hong Kong cents per share [1] Industry Insights - The growth in total revenue is attributed to the recovery in the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models [1] - There is an increasing demand for precise omnichannel marketing solutions, driven by the industry's shift [1]
梅斯健康股东将股票由Merrill Lynch Far East Limited转入中国国际金融香港证券 转仓市值8821.08万港元